BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22967380)

  • 21. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation of WT1 and VEGF Expression with Angiogenesis in Bone Marrow Biopsies of Multiple Myeloma Patients].
    Li GJ; Ding H; Yang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):733-6. PubMed ID: 26117027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
    Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG
    Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low differentiated microvascular density and low expression of platelet-derived growth factor-BB (PDGF-BB) predict distant metastasis and poor prognosis in clear cell renal cell carcinoma.
    Qi L; Du J; Zhang Z; Diao L; Chen X; Yao X
    BJU Int; 2013 Aug; 112(4):E415-23. PubMed ID: 23879920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance.
    Marković O; Marisavljević D; Cemerikić V; Vidović A; Perunicić M; Todorović M; Elezović I; Colović M
    Med Oncol; 2008; 25(4):451-7. PubMed ID: 18449811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
    Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study on the role of angiogenesis and related factors in leukemias].
    Zhang Y; Gu J; Wang M; Ma L; Wang XL; He B; Sun M
    Zhonghua Xue Ye Xue Za Zhi; 2005 Mar; 26(3):175-8. PubMed ID: 15946533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coordinated increase in serum platelet-derived growth factor-BB and transforming growth factor-β1 in patients with chronic pancreatitis.
    Adrych K; Smoczynski M; Stojek M; Sledzinski T; Korczynska J; Goyke E; Swierczynski J
    Pancreatology; 2011; 11(4):434-40. PubMed ID: 21921666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy.
    Sezer O; Niemöller K; Kaufmann O; Eucker J; Jakob C; Zavrski I; Possinger K
    Eur J Haematol; 2001 Apr; 66(4):238-44. PubMed ID: 11380603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
    Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV
    Leukemia; 2004 Mar; 18(3):624-7. PubMed ID: 14749707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia.
    Zhelyazkova AG; Tonchev AB; Kolova P; Ivanova L; Gercheva L
    Scand J Clin Lab Invest; 2008; 68(6):492-500. PubMed ID: 18609087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
    Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
    J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.
    Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Wellik LA; Fonseca R; Lust JA; Witzig TE; Kyle RA; Greipp PR; Rajkumar SV
    Bone Marrow Transplant; 2004 Aug; 34(3):235-9. PubMed ID: 15170170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis.
    Riccieri V; Stefanantoni K; Vasile M; Macrì V; Sciarra I; Iannace N; Alessandri C; Valesini G
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S46-52. PubMed ID: 21586218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
    Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increase in serum platelet-derived growth factor (PDGF)-BB reflects lymph node involvement in esophageal cancer patients independently from platelet count.
    Krzystek-Korpacka M; Diakowska D; Gamian A; Matusiewicz M
    Exp Oncol; 2011 Sep; 33(3):140-4. PubMed ID: 21956466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas.
    Matsumoto S; Yamada Y; Narikiyo M; Ueno M; Tamaki H; Miki K; Wakatsuki K; Enomoto K; Yokotani T; Nakajima Y
    Anticancer Res; 2007; 27(4B):2409-14. PubMed ID: 17695532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.